|View printer-friendly version|
|St. Jude Medical Announces Acquisition and CE Mark Approval of World's First Leadless Pacemaker|
Nanostim leadless pacemaker represents one of the most important advances in the history of pacing technology
The Nanostim(TM) leadless pacemaker is less than 10 percent the size of a conventional pacemaker. (Photo: Business Wire)
Unlike conventional pacemakers that require a more invasive surgery, the Nanostim™
leadless pacemaker is designed to be implanted directly into the
heart via a minimally invasive procedure. The device is delivered using
a steerable catheter through the femoral vein, eliminating the need to
surgically create a pocket for the pacemaker and insulated wires (called
leads) that have historically been recognized as the most vulnerable
component of pacing systems. The Nanostim leadless pacemaker recently
received CE Mark approval and will be available soon in select European
markets. It also recently received
“The Nanostim leadless pacemaker represents one of the most important
advances in the history of pacing technology, and builds on St. Jude
Medical’s strong history of pacing innovation – beginning with the first
implantable pacemaker in 1958 through the introduction of quadripolar
cardiac resynchronization therapy pacing,” said
The Nanostim leadless pacemaker is less than 10 percent the size of a conventional pacemaker. The small size of the device and lack of a surgical pocket, coupled with the exclusion of a lead, improves patient comfort and can reduce complications, including device pocket-related infection and lead failure. The elimination of the visible lump and scar at a conventional pacemaker’s implant site, in addition to the removal of patient activity restrictions that may prevent the dislodgement or damage to a conventional lead, will potentially improve the quality of life for patients with this technology by allowing most to continue living active, uninhibited lifestyles. The device is supported by the St. Jude Medical Merlin™ Programmer that is also used to interrogate and program the company’s other pacemakers and implantable cardioverter defibrillators (ICDs).
“For the past 40 years the therapeutic promise of leadless pacing has
been discussed, but until now, no one has been able to overcome the
technical challenges,” said Dr.
The Nanostim leadless pacemaker was designed to be fully retrievable so that the device can be readily repositioned during the implant procedure and later retrieved if necessary, such as at the time of normal battery replacement. Initial results from the LEADLESS study, a prospective, single-arm, multicenter study evaluating patients with the Nanostim leadless pacemaker, were presented earlier this year and demonstrated overall device performance comparable to conventional pacemakers. Total implant procedure times averaged 28 minutes. Even with miniaturization, the device battery is expected to have an average lifespan of more than 9 years at 100 percent pacing, or more than 13 years at 50 percent pacing.
Cardiac pacemakers are used to treat bradycardia, which is a heart rate that is too slow. These devices monitor the heart and provide electrical stimulation when the heart beats too slowly for each patient's specific physiological requirements. More than four million people worldwide have an implanted pacemaker or other cardiac rhythm management device, and an additional 700,000 patients receive the devices each year.
Commenting on the acquisition, Nanostim Chief Executive Officer
In connection with this transaction, BofA Merrill Lynch is acting as
financial advisor and
Nanostim, an early-stage medical device start-up company based in
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the